Clinical Application of Protein Induced by Vitamin K Antagonist-Ii As a Biomarker in Hepatocellular Carcinoma

Hao Xing,Cunling Yan,Liming Cheng,Nianyue Wang,Shuyang Dai,Jianyong Yuan,Wenfeng Lu,Zhouchong Wang,Jun Han,Yijie Zheng,Tian Yang
DOI: https://doi.org/10.1007/s13277-016-5443-x
2016-01-01
Tumor Biology
Abstract:Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Early diagnosis improves the prognosis. Protein induced by vitamin K antagonist-II (PIVKA-II) is an effective serum biomarker for HCC diagnosis and prognosis. Combined with another serum biomarker α-fetoprotein (AFP), the sensitivity and specificity of HCC diagnosis can be improved to a maximum of 94 and 98.5 %, respectively. PIVKA-II alone or in combination with AFP and/or AFP-L3 was effective in predicting the treatment response and clinical outcome of curative hepatic resection, chemotherapy, targeted therapy, radiotherapy, and liver transplantation. Japanese clinical guidelines recommend the combined use of PIVKA-II and AFP for the diagnosis of HCC, management of high-risk population, and prognosis of anticancer treatment. Further, PIVKA-II as a functional target promoted HCC cell proliferation, invasion, and metastasis by activating c-Met and other signal transduction pathways. Inhibition of PIVKA-II may provide a selective and effective therapy for HCC.
What problem does this paper attempt to address?